MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/90/0.1/20.12.24 | Market Closed - Börse Stuttgart 12:16:07 05/06/2024 am IST | ||
| 0.214 EUR | +5.94% |
|
| Current month | +28.14% | ||
| 1 month | +62.12% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 0.214 | +5.94% |
| 03/24/03 | 0.202 | +20.96% |
| 31/24/31 | 0.167 | +12.08% |
| 30/24/30 | 0.149 | +10.37% |
| 29/24/29 | 0.135 | -16.15% |
Delayed Quote Börse Stuttgart
Last update June 05, 2024 at 12:16 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MB3F27 |
| ISIN | DE000MB3F270 |
| Date issued | 08/02/2023 |
| Strike | 90 $ |
| Maturity | 20/12/2024 (199 Days) |
| Parity | 10 : 1 |
| Emission price | 0.25 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.51 € |
|---|---|
| Lowest since issue | 0.017 € |
| Spread | 0.021 € |
| Spread % | 11.60% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6
USD
Average target price
172.1
USD
Spread / Average Target
+8.49%
- Stock Market
- Warrants
- Warrant
